← Back to Company DatabaseVisit Website
Kopra Bio
Genetically engineered viruses that teach the immune system to kill cancer.
Pre-seed / SeedSan Francisco, CAFounded 2024
About
Kopra Bio develops oncolytic viral immunotherapy using its InViTE (In Vivo Tumor Editing) platform developed at UCSF. The technology utilizes genetically engineered viruses designed to selectively infect and destroy cancer cells. Initially targeting glioblastoma, their treatment improved survival from 0% to 90% in the most challenging brain cancer models.
Total Funding
$500KKey Product
InViTE viral immunotherapy platformGeography
North AmericaKey Investors
Y CombinatorAndreessen HorowitzBoutique Venture Partners
Focus Areas
Treatment (Therapeutics)
Technology
ImmunotherapyOther
Cancer Types
Brain
Last updated: Feb 4, 2026